Vertex Pharmaceuticals Q2 Adj $(12.83) Misses $4.14 Estimate, Sales $2.65B Miss $2.66B Estimate
Portfolio Pulse from Benzinga Newsdesk
Vertex Pharmaceuticals (NASDAQ:VRTX) reported a significant quarterly loss of $(12.83) per share, missing the analyst consensus estimate of $4.14 by 409.9%. Sales were $2.65 billion, slightly below the $2.66 billion estimate. This represents a 6.14% increase in sales from the same period last year.
August 01, 2024 | 8:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Vertex Pharmaceuticals reported a significant quarterly loss of $(12.83) per share, missing the analyst consensus estimate of $4.14 by 409.9%. Sales were $2.65 billion, slightly below the $2.66 billion estimate. This represents a 6.14% increase in sales from the same period last year.
The significant miss on earnings per share (EPS) and the slight miss on sales estimates are likely to negatively impact Vertex Pharmaceuticals' stock price in the short term. The large discrepancy between the reported EPS and the analyst estimates, along with the year-over-year decrease in EPS, will likely cause investor concern.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100